article thumbnail

Global decentralized studies will become a standard clinical trial design approach

The Pharma Data

“Studies will embrace decentralized trial approaches as design options earlier in the clinical trial planning process,” Reites said. Sponsors and CROs will continue to be eager to bounce back and accelerate the drug development process after significant delays caused by the pandemic,” Reites said. .

article thumbnail

Common Pitfalls in Preparing an IND Application

Advarra

As a drug successfully makes it through the development process, sponsors will inevitably need to submit a new drug application (NDA) to the Food and Drug Administration (FDA). Failure to Have a Pre-Investigational New Drug (IND) Meeting. Failure to Have a Pre-Investigational New Drug (IND) Meeting.